Reducing fibrosis progression of biliary atresia by continuous administration of aducanumab at low dose: A potential treatment

Biliary atresia (BA) is a disease in which the intra- and extrahepatic bile ducts are blocked, leading to cholestatic liver cirrhosis and liver failure. Kasai portoenterostomy (KPE) and liver transplantation are the gold treatment methods since effective medical interventions are lacking. Limited by the availability of early screening methods, children with biliary atresia are often not diagnosed in time, which has a negative impact on postoperative recovery. Beta-amyloid (Aβ) is the main pathological feature of Alzheimer’s disease and is deposited in the liver tissue of biliary atresia. Aducanumab is the first targeted drug based on Alzheimer’s pathogenesis that effectively reduces the load of Aβ. Thus, we hypothesized that low-dose aducanumab may be used for biliary atresia, which would slow down / prevent progressive liver cirrhosis in BA patients.